Published in Clin Exp Immunol on November 01, 2012
Regulatory multitasking of tolerogenic dendritic cells - lessons taken from vitamin d3-treated tolerogenic dendritic cells. Front Immunol (2013) 1.06
Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies. Hum Vaccin Immunother (2014) 0.79
Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients. Bone Marrow Transplant (2016) 0.78
Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine. Stem Cell Res Ther (2015) 0.77
CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseases. Clin Dev Immunol (2013) 0.77
Idiotype-specific CD4(+) T cells eradicate disseminated myeloma. Leukemia (2015) 0.77
Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma. Br J Haematol (2014) 0.77
p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression. Nat Commun (2014) 0.77
Immunotherapy strategies for multiple myeloma: the present and the future. Immunotherapy (2013) 0.76
Antibody-based therapeutics for the treatment of human B cell malignancies. Curr Allergy Asthma Rep (2013) 0.75
Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage-colony stimulating factor and interleukin-2 surface modified MB49 bladder cancer stem cells vaccine. Cancer Med (2017) 0.75
Dendritic Cell Therapies for Hematologic Malignancies. Mol Ther Methods Clin Dev (2017) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods (1999) 17.06
Multiple myeloma. N Engl J Med (2011) 10.38
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Tumor antigens recognized by T lymphocytes. Annu Rev Immunol (1994) 6.16
Multiple myeloma. Blood (2008) 5.88
Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol (1979) 2.60
Active immunization against cancer with dendritic cells: the near future. Int J Cancer (2001) 2.22
Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today (1995) 1.91
Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med (1996) 1.83
A murine model of human myeloma bone disease. Bone (1997) 1.53
Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res (2002) 1.37
Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci U S A (1996) 1.27
Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood (2007) 1.26
The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J (2000) 1.25
Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood (2002) 1.23
Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev (2008) 1.22
Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol (2000) 1.19
Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood (2001) 1.15
Preclinical models of bone metastases. Semin Oncol (2001) 1.13
Dendritic cells hold promise for immunotherapy. Immunol Today (1997) 1.10
Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clin Cancer Res (2005) 1.08
Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood (2003) 1.05
Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol (2002) 1.03
Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia (2005) 0.98
Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant (2000) 0.97
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br J Haematol (2010) 0.95
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol (2004) 0.95
Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth. Cancer Res (2008) 0.94
Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells. Exp Oncol (2004) 0.89
Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma. Front Biosci (2007) 0.88
Deletion of idiotype (Id)-specific T cells in multiple myeloma. Acta Oncol (2000) 0.83
Novel immunotherapies. Cancer J (2009) 0.82
Immunotherapy in multiple myeloma: current strategies and future prospects. Expert Rev Vaccines (2003) 0.81
Preclinical development of hybrid cell vaccines for multiple myeloma. Eur J Haematol (2007) 0.78
Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell (1996) 16.73
Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet (1994) 10.14
Modular chemistry: secondary building units as a basis for the design of highly porous and robust metal-organic carboxylate frameworks. Acc Chem Res (2001) 9.19
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol (1999) 9.11
Regulatory element detection using correlation with expression. Nat Genet (2001) 8.92
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA (2001) 8.80
RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999) 8.55
Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage (2004) 8.50
The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J (2001) 7.97
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med (2000) 7.48
Notch signalling controls pancreatic cell differentiation. Nature (1999) 7.18
Crystal structure of a T-cell receptor beta-chain complexed with a superantigen. Nature (1996) 7.11
Refined structure of alpha beta-tubulin at 3.5 A resolution. J Mol Biol (2001) 7.08
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 6.70
Ecological degradation in protected areas: the case of Wolong Nature Reserve for giant pandas. Science (2001) 6.52
PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet (1999) 6.18
Mechanical unfolding intermediates in titin modules. Nature (1999) 6.12
Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science (1999) 6.04
Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene (2006) 5.86
Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med (1998) 5.54
Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporos Int (1995) 5.22
A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest (2001) 4.98
A genomic screen of autism: evidence for a multilocus etiology. Am J Hum Genet (1999) 4.96
Structural evidence for the authenticity of the human retinoblastoma gene. Science (1987) 4.67
An rpsL cassette, janus, for gene replacement through negative selection in Streptococcus pneumoniae. Appl Environ Microbiol (2001) 4.59
A fixative for intestinal parasites permitting the use of concentration and permanent staining procedures. Am J Clin Pathol (1977) 4.58
Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy. Med Phys (1994) 4.50
Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet (1995) 4.45
A mouse model for spinal muscular atrophy. Nat Genet (2000) 4.37
Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol (1998) 4.17
Genome-wide association studies establish that human intelligence is highly heritable and polygenic. Mol Psychiatry (2011) 4.16
Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol (2007) 4.13
Estimation of pleiotropy between complex diseases using single-nucleotide polymorphism-derived genomic relationships and restricted maximum likelihood. Bioinformatics (2012) 3.97
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation (2001) 3.96
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology (2006) 3.93
Integrating primary medical care with addiction treatment: a randomized controlled trial. JAMA (2001) 3.91
Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res (2001) 3.89
PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol (2000) 3.81
Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res (1999) 3.69
Glutamate release promotes growth of malignant gliomas. Nat Med (2001) 3.67
Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A (2000) 3.61
Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet (1996) 3.58
Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest (2000) 3.57
Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science (1996) 3.54
Latent and active p53 are identical in conformation. Nat Struct Biol (2001) 3.47
Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet (2004) 3.45
Signaling and transcription in T helper development. Annu Rev Immunol (2000) 3.44
Ca2+ channel selectivity at a single locus for high-affinity Ca2+ interactions. Neuron (1995) 3.39
Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med (1999) 3.38
Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int (2016) 3.30
A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling. J Biol Chem (2000) 3.26
Axon-glia interactions and the domain organization of myelinated axons requires neurexin IV/Caspr/Paranodin. Neuron (2001) 3.20
Crystal structure of constitutive endothelial nitric oxide synthase: a paradigm for pterin function involving a novel metal center. Cell (1998) 3.20
Building a dictionary for genomes: identification of presumptive regulatory sites by statistical analysis. Proc Natl Acad Sci U S A (2000) 3.18
Structure of translation factor eIF4E bound to m7GDP and interaction with 4E-binding protein. Nat Struct Biol (1997) 3.14
Hormone-dependent, CARM1-directed, arginine-specific methylation of histone H3 on a steroid-regulated promoter. Curr Biol (2001) 3.09
Assignment of the membrane attachment, DNA binding, and transcriptional activation domains of sterol regulatory element-binding protein-1 (SREBP-1). J Biol Chem (1994) 3.09
Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol (1999) 3.08
Induction of apoptosis by the low-affinity NGF receptor. Science (1993) 3.04
Mechanical design of proteins studied by single-molecule force spectroscopy and protein engineering. Prog Biophys Mol Biol (2000) 3.00
Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med (1993) 2.96
TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene (2008) 2.94
Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum (1998) 2.91
RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun (2002) 2.88
Identification of coryneform bacterial isolates by ribosomal DNA sequence analysis. J Clin Microbiol (2000) 2.87
Search for a resonance decaying into WZ boson pairs in pp collisions. Phys Rev Lett (2010) 2.83
Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res (1997) 2.80
Validation of near-infrared spectroscopy in humans. J Appl Physiol (1985) (1994) 2.77
tRNA splicing. J Biol Chem (1998) 2.77
Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg (1998) 2.75
Dentinogenesis imperfecta 1 with or without progressive hearing loss is associated with distinct mutations in DSPP. Nat Genet (2001) 2.75
Retrohoming of a bacterial group II intron: mobility via complete reverse splicing, independent of homologous DNA recombination. Cell (1998) 2.74
Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol (2000) 2.73
Contrast extravasation on CT predicts mortality in primary intracerebral hemorrhage. AJNR Am J Neuroradiol (2007) 2.69
Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol (1999) 2.69
Feasibility of a high-speed gamma-camera design using the high-yield-pileup-event-recovery method. J Nucl Med (2001) 2.69
Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A (2001) 2.64
Targeted disruption of the murine VCAM1 gene: essential role of VCAM-1 in chorioallantoic fusion and placentation. Genes Dev (1995) 2.61
Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant (2007) 2.61
Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. J Virol (1997) 2.59
Solution structure of BID, an intracellular amplifier of apoptotic signaling. Cell (1999) 2.58
Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression. Nat Genet (1999) 2.57
Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A (2001) 2.56
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis (2013) 2.52
Fps1p controls the accumulation and release of the compatible solute glycerol in yeast osmoregulation. Mol Microbiol (1999) 2.52
LIM homeodomain factors Lhx3 and Lhx4 assign subtype identities for motor neurons. Cell (1998) 2.50
Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family. Circ Res (1998) 2.49
The Dentin matrix protein 1 (Dmp1) is specifically expressed in mineralized, but not soft, tissues during development. J Dent Res (2003) 2.48
Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res (1996) 2.47
Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest (2001) 2.45
Identification of a putative alternate sigma factor and characterization of a multicomponent regulatory cascade controlling the expression of Pseudomonas syringae pv. syringae Pss61 hrp and hrmA genes. J Bacteriol (1994) 2.45
Observation of the spin-Seebeck effect in a ferromagnetic semiconductor. Nat Mater (2010) 2.44
Nephrin mediates actin reorganization via phosphoinositide 3-kinase in podocytes. Kidney Int (2007) 2.44
PKA: a portrait of protein kinase dynamics. Biochim Biophys Acta (2004) 2.43
Identification of a PY motif in the epithelial Na channel subunits as a target sequence for mutations causing channel activation found in Liddle syndrome. EMBO J (1996) 2.39
A group II intron RNA is a catalytic component of a DNA endonuclease involved in intron mobility. Cell (1995) 2.37